KPTI vs. OPAD
KPTI (Karyopharm Therapeutics Inc.) and OPAD (Offerpad Solutions Inc.) are both stocks. KPTI operates in Biotechnology (Healthcare), while OPAD operates in Real Estate - Services (Real Estate). Over the past 5 years, KPTI returned -43.70%/yr vs -67.51%/yr for OPAD. At a 0.22 correlation, their price movements are largely independent.
Performance
KPTI vs. OPAD - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KPTI achieves a 15.49% return, which is significantly higher than OPAD's -55.36% return.
KPTI
- 1D
- -6.39%
- 1M
- -1.62%
- YTD
- 15.49%
- 6M
- 44.31%
- 1Y
- 89.31%
- 3Y*
- -36.47%
- 5Y*
- -43.70%
- 10Y*
- -23.75%
OPAD
- 1D
- -12.51%
- 1M
- -19.39%
- YTD
- -55.36%
- 6M
- -70.81%
- 1Y
- -52.20%
- 3Y*
- -61.68%
- 5Y*
- -67.51%
- 10Y*
- —
KPTI vs. OPAD - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
KPTI Karyopharm Therapeutics Inc. | 15.49% | -27.45% | -21.82% | -74.56% | -47.12% | -58.46% | 0.78% |
OPAD Offerpad Solutions Inc. | -55.36% | -57.54% | -72.20% | 48.39% | -92.80% | -41.82% | 8.06% |
Correlation
The correlation between KPTI and OPAD is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Dec 14, 2020 | 0.22 |
Fundamentals
KPTI:
$210.08M
OPAD:
$24.95M
KPTI:
-$13.00
OPAD:
-$1.16
KPTI:
0.84
OPAD:
0.04
KPTI:
$151.12M
OPAD:
$487.19M
KPTI:
$145.13M
OPAD:
$37.09M
KPTI:
-$93.05M
OPAD:
-$29.30M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KPTI vs. OPAD — Risk / Return Rank
KPTI
OPAD
KPTI vs. OPAD - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and Offerpad Solutions Inc. (OPAD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KPTI | OPAD | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.20 | ||
| Sortino ratioReturn per unit of downside risk | +0.95 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.11 | +0.11 |
| Calmar ratioReturn relative to maximum drawdown | 1.86 | -0.57 | +2.43 |
| Martin ratioReturn relative to average drawdown | 4.59 | -0.77 | +5.36 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KPTI | OPAD | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.95 | -0.25 | +1.20 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.46 | -0.52 | +0.05 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.28 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.27 | -0.51 | +0.25 |
Drawdowns
KPTI vs. OPAD - Drawdown Comparison
The maximum KPTI drawdown since its inception was -99.50%, roughly equal to the maximum OPAD drawdown of -99.82%. Use the drawdown chart below to compare losses from any high point for KPTI and OPAD.
Loading charts...
Drawdown Indicators
| KPTI | OPAD | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.50% | -99.82% | +0.32% |
Max Drawdown (1Y)Largest decline over 1 year | -48.36% | -91.33% | +42.97% |
Max Drawdown (3Y)Largest decline over 3 years | -89.32% | -96.35% | +7.03% |
Max Drawdown (5Y)Largest decline over 5 years | -98.36% | -99.82% | +1.46% |
Max Drawdown (10Y)Largest decline over 10 years | -99.15% | — | — |
Current DrawdownCurrent decline from peak | -98.80% | -99.82% | +1.02% |
Average DrawdownAverage peak-to-trough decline | -75.28% | -82.08% | +6.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.53% | 68.07% | -48.54% |
Volatility
KPTI vs. OPAD - Volatility Comparison
The current volatility for Karyopharm Therapeutics Inc. (KPTI) is 24.86%, while Offerpad Solutions Inc. (OPAD) has a volatility of 30.56%. This indicates that KPTI experiences smaller price fluctuations and is considered to be less risky than OPAD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KPTI | OPAD | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 24.86% | 30.56% | -5.70% |
Volatility (6M)Calculated over the trailing 6-month period | 62.32% | 75.65% | -13.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 94.32% | 210.71% | -116.39% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 94.91% | 131.29% | -36.38% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.51% | 125.52% | -39.01% |
Dividends
KPTI vs. OPAD - Dividend Comparison
Neither KPTI nor OPAD has paid dividends to shareholders.
Financials
KPTI vs. OPAD - Financials Comparison
This section allows you to compare key financial metrics between Karyopharm Therapeutics Inc. and Offerpad Solutions Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KPTI vs. OPAD - Profitability Comparison
KPTI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a gross profit of 33.72M and revenue of 35.07M. Therefore, the gross margin over that period was 96.2%.
OPAD - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Offerpad Solutions Inc. reported a gross profit of 5.56M and revenue of 80.08M. Therefore, the gross margin over that period was 6.9%.
KPTI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported an operating income of -26.76M and revenue of 35.07M, resulting in an operating margin of -76.3%.
OPAD - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Offerpad Solutions Inc. reported an operating income of -9.03M and revenue of 80.08M, resulting in an operating margin of -11.3%.
KPTI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Karyopharm Therapeutics Inc. reported a net income of -22.39M and revenue of 35.07M, resulting in a net margin of -63.9%.
OPAD - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Offerpad Solutions Inc. reported a net income of -10.13M and revenue of 80.08M, resulting in a net margin of -12.7%.
Frequently Asked Questions
KPTI and OPAD have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
OPAD has higher volatility (30.56%) compared to KPTI (24.86%). In terms of maximum drawdown, KPTI dropped -99.50% vs OPAD's -99.82%.
KPTI currently has the higher Sharpe Ratio (0.95 vs -0.25), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KPTI and OPAD
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer